Article
Cardiac & Cardiovascular Systems
Ana Morales, Jessica Goehringer, Despina Sanoudou
Summary: In the era of Precision Medicine, the approach to disease diagnosis, treatment, and prevention, including in Cardiology, is being transformed by genomics approaches. The American Heart Association emphasizes the importance of genetic counseling in delivering quality cardiovascular genetics care. With the increasing number and complexity of cardiogenetic tests, there is a need for specialized cardiovascular genetic counselors. Advanced training, along with online services, telemedicine, and patient-facing digital tools, are crucial for providing effective care. The timely implementation of these reforms is essential for translating scientific advancements into measurable benefits for patients with heritable cardiovascular disease and their families.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Oncology
Hong Truong, Rania Sheikh, Ritesh Kotecha, Yelena Kemel, Peter A. Reisz, Andrew T. Lenis, Nikita N. Mehta, Aliya Khurram, Vijai Joseph, Diana Mandelker, Alicia Latham, Ozge Ceyhan-Birsoy, Marc Ladanyi, Neil J. Shah, Michael F. Walsh, Martin H. Voss, Chung-Han Lee, Paul Russo, Jonathan A. Coleman, A. Ari Hakimi, Darren R. Feldman, Zsofia K. Stadler, Mark E. Robson, Robert J. Motzer, Kenneth Offit, Sujata Patil, Maria Carlo
Summary: Patients with early-onset RCC have a high frequency of germline P/LP variants in genes associated with hereditary RCC and other cancer predispositions. Genetic testing has the highest yield when patients have clinical phenotypes suggestive of underlying RCC gene mutations.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Xiaogan Wang, Yuqin Song, Wei Chen, Ning Ding, Weiping Liu, Yan Xie, Yinan Wang, Jun Zhu, Changqing Zeng
Summary: The study discovered germline mutations of DNA repair genes, especially mismatch repair (MMR) genes, in mantle cell lymphoma (MCL), shedding light on genetic predispositions for MCL.
Article
Genetics & Heredity
Diana Cristina Perez-Ibave, Maria Lourdes Garza-Rodriguez, Maria Fernanda Noriega-Iriondo, Sonia Maria Flores-Moreno, Manuel Ismael Gonzalez-Geroniz, Absalon Espinoza-Velazco, Ana Lilia Castruita-Avila, Fernando Alcorta-Nunez, Omar Alejandro Zayas-Villanueva, Juan Francisco Gonzalez-Guerrero, Adelina Alcorta-Garza, Oscar Vidal-Gutierrez, Carlos Horacio Burciaga-Flores
Summary: This research studied the implementation of genetic counseling and germline variants testing for hereditary cancer syndromes in an oncologic center in Mexico. Around 63.90% of probands and 36.09% of relatives received genetic testing, with 85 probands found to have at least one germline variant. The most common syndrome detected was hereditary breast and ovarian cancer syndrome (HBOC), followed by hereditary non-polyposic cancer syndrome (HNPCC or Lynch syndrome) and other high cancer risk syndromes.
Article
Oncology
Brittany C. McGill, Claire E. Wakefield, Katherine M. Tucker, Rebecca A. Daly, Mark W. Donoghoe, Janine Vetsch, Meera Warby, Noemi A. Fuentes-Bolanos, Kristine Barlow-Stewart, Judy Kirk, Eliza Courtney, Tracey A. O'Brien, Glenn M. Marshall, Mark Pinese, Mark J. Cowley, Vanessa Tyrrell, Rebecca J. Deyell, David S. Ziegler, Kate Hetherington
Summary: In childhood cancer precision medicine trials, more than 10% of children may have pathogenic or likely pathogenic variants in cancer predisposition genes identified through germline genome sequencing. These findings can greatly impact diagnosis, treatment, and the future cancer risk for both the child and their family. Understanding parents' perspectives on this sequencing is crucial for its successful implementation in clinical settings.
Article
Oncology
Ying L. Liu, Anna Maio, Yelena Kemel, Erin E. Salo-Mullen, Margaret Sheehan, Prince Ray Tejada, Magan Trottier, Angela G. Arnold, Megan Harlan Fleischut, Alicia Latham, Maria Carlo, Yonina R. Murciano-Goroff, Michael F. Walsh, Diana Mandelker, Nikita Mehta, Chaitanya Bandlamudi, Kanika Arora, Ahmet Zehir, Michael F. Berger, David B. Solit, Carol Aghajanian, Luis A. Diaz, Mark E. Robson, Carol L. Brown, Kenneth Offit, Jada G. Hamilton, Zsofia K. Stadler
Summary: The study reveals disparities in genetic counseling among individuals of different backgrounds. Despite high rates of clinically important genetic findings in all groups, Black patients were less likely to receive recommended counseling compared to White patients. Even after removing barriers, non-White, particularly Black patients, were less likely to receive recommended genetics care, which may have implications for their cancer treatment and families.
Article
Hematology
Peng Li, Sara Brown, Margaret Williams, Thomas White, Wei Xie, Wei Cui, Deniz Peker, Li Lei, Christian A. Kunder, Huan-You Wang, Sarah S. Murray, Jennie Vagher, Tibor Kovacsovics, Jay L. Patel
Summary: The study revealed significant differences between patients with HM carrying DDX41 CV and those with VUS, including older age, male predominance, frequent co-occurrence of somatic DDX41 variants, and lower somatic mutation burden in CV patients. These findings underscore the distinct clinical entity defined by germline DDX41 variants and emphasize the need for gene-specific diagnostic and clinical management guidelines.
Article
Oncology
Benoit Mazel, Geoffrey Bertolone, Amandine Baurand, Elodie Cosset, Caroline Sawka, Marion Robert, Elodie Gautier, Allan Lancon, Manon Reda, Laure Favier, Valentin Derangere, Corentin Richard, Christine Binquet, Romain Boidot, Vincent Goussot, Juliette Albuisson, Francois Ghiringhelli, Laurence Faivre, Sophie Nambot
Summary: This study aimed to provide genetic counseling and analysis for tumor patients to accurately identify genetic predispositions related to tumor management. The results showed that 7.4% of patients had undiagnosed genetic predispositions, but only 6.3% of patients were affected in their oncological management. Further efforts are needed to improve oncologists' understanding and guidance in genetic analysis.
Article
Genetics & Heredity
Marie Coudert, Youenn Drouet, Helene Delhomelle, Magali Svrcek, Patrick R. Benusiglio, Florence Coulet, Dana Farengo Clark, Bryson W. Katona, Liselotte P. van Hest, Lizet E. van der Kolk, Annemieke Cats, Jolanda M. van Dieren, Bita Nehoray, Thomas Slavin, Isabel Spier, Robert Huneburg, Silvana Lobo, Carla Oliveira, Lise Boussemart, Laure Masson, Jean Chiesa, Mathias Schwartz, Bruno Buecher, Lisa Golmard, Anne-Marie Bouvier, Valerie Bonadona, Dominique Stoppa-Lyonnet, Christine Lasset, Chrystelle Colas
Summary: This study provides the first risk estimates of diffuse gastric cancer for carriers of germline CTNNA1 PV, based on data from the largest series of CTNNA1 families. These risk estimates will improve the management and surveillance of patients with CTNNA1 PV and support the inclusion of CTNNA1 in germline testing panels.
JOURNAL OF MEDICAL GENETICS
(2022)
Review
Health Care Sciences & Services
Alina Nicheperovich, Andrea Townsend-Nicholson
Summary: This review suggests that detection of Smo variants through tumor profiling could lead to increased precision and improved outcomes of anti-cancer treatments.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Urology & Nephrology
Sophia M. M. Abusamra, Marissa A. A. Solorzano, Mallory Luke, Jake Quarles, Michelle F. F. Jacobs, Sanjay Das, Amy Kasputis, Linda A. A. Okoth, Milan Patel, Mariana Seymore, Megan E. V. Caram, Rodney L. L. Dunn, Sofia D. D. Merajver, Elena M. M. Stoffel, Zachery R. R. Reichert, Todd M. M. Morgan
Summary: The study demonstrated the effectiveness of clinician-led genetic counseling in expanding access to appropriate germline genetic testing for prostate cancer patients. Patient satisfaction was high, with majority reporting satisfaction with the quality of counseling and over two-thirds of patients choosing to undergo genetic testing.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
K. Pauley, C. Koptiuch, S. Greenberg, W. Kohlmann, J. Jeter, S. Colonna, T. Werner, C. Kinsey, G. Gilcrease, J. Weis, J. Whisenant, V Florou, I Garrido-Laguna
Summary: This study evaluated discrepancies between tumor genomic profiling and germline genetic testing, and found that unrecognized germline pathogenic variants may harm patients by missing hereditary syndromes and targeted therapy opportunities. The findings highlight the importance of comprehensive germline assessment and referring patients for genetic evaluation regardless of somatic testing outcomes.
Article
Oncology
Flavia Carolina Pozzobon, Gemma Tell-Marti, Neus Calbet-Llopart, Alicia Barreiro, Natalia Espinosa, Miriam Potrony, Beatriz Alejo, Sebastian Podlipnik, Marc Combalia, Joan Anton Puig-Butille, Cristina Carrera, Josep Malvehy, Susana Puig
Summary: The research reveals that genetic variants associated with low nevus count and melanoma risk are linked to specific dermoscopic features, which are more typical of de novo melanomas and melanomas with a poorer prognosis. Melanomas with red hair color MC1R variants carriers have a lower total dermoscopy score and fewer blotches compared to non-carriers.
PIGMENT CELL & MELANOMA RESEARCH
(2021)
Article
Oncology
Sonja Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni, Attilio Gabbas, Herve Ghesquieres, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Herve Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van den Berg, David J. Van den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager, Nathaniel Rothman
Summary: The risk of lymphoma is increased for relatives with common non-Hodgkin lymphoma (NHL) subtypes, suggesting a shared genetic susceptibility. Through genome-wide association studies and genetic correlation analysis, we discovered significant loci associated with subsets of NHL subtypes and found heterogeneity in the extent of shared heritability among subtypes. Our findings demonstrate partially shared heritability and unique genetic architecture for each NHL subtype.
Review
Cell Biology
Shahood Fazal, Malik Bisserier, Lahouaria Hadri
Summary: PAH is a rare and chronic lung disease characterized by occlusion of small pulmonary arteries, leading to increased pulmonary vascular resistance and right ventricular pressure overload. Advances in multi-omics approaches and high-throughput sequencing have helped identify genetic variants in PAH patients, contributing to precision medicine and the development of gene-editing technologies and gene therapies as alternative approaches to treating genetic disorders in PAH.
Article
Oncology
Erin F. Cobain, Yi-Mi Wu, Rashmi Chugh, Francis Worden, David C. Smith, Scott M. Schuetze, Mark M. Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F. Schott, Megan E. V. Caram, Daniel F. Hayes, Elena M. Stoffel, Michelle F. Jacobs, Chandan Kumar-Sinha, Xuhong Cao, Rui Wang, David Lucas, Yu Ning, Erica Rabban, Janice Bell, Sandra Camelo-Piragua, Aaron M. Udager, Marcin Cieslik, Robert J. Lonigro, Lakshmi P. Kunju, Dan R. Robinson, Moshe Talpaz, Arul M. Chinnaiyan
Summary: The study aimed to determine the clinical benefit of NGS profiling in patients with advanced solid tumors. Results showed a high rate of potentially actionable genomic alterations in diverse cancers, recommending germline testing for all patients with advanced cancer. Additionally, the study highlighted the importance of comprehensive NGS profiling for rare cancers like carcinoma of unknown primary origin.
Article
Oncology
Shenin A. Dettwyler, Erika S. Koeppe, Michelle F. Jacobs, Elena M. Stoffel
Summary: Advances in cancer genetics have increased the detection rates of germline pathogenic variants. Retesting patients with previously uninformative results could lead to earlier identification of PV/LPVs, impacting screening recommendations and clinical management. Personal or familial history changes were common reasons for retesting, while no specific factors were predictive of PV/LPV identification.
Editorial Material
Urology & Nephrology
Samantha E. Greenberg, Michelle F. Jacobs
Correction
Oncology
Shenin A. Dettwyler, Erika S. Koeppe, Michelle F. Jacobs, Elena M. Stoffel
Article
Oncology
Anthony Scott, Arathi Mohan, Sarah Austin, Erika Amini, Shelby Raupp, Brittany Pannecouk, Michael J. Kelley, Goutham Narla, Nithya Ramnath
Summary: This study investigated the number of veterans who would benefit from genetic testing and identified a certain percentage of veterans with potentially pathogenic germline variants. The findings underscore the importance of medical genetics in oncologic care for veterans.
JCO ONCOLOGY PRACTICE
(2022)
Article
Urology & Nephrology
Sophia M. M. Abusamra, Marissa A. A. Solorzano, Mallory Luke, Jake Quarles, Michelle F. F. Jacobs, Sanjay Das, Amy Kasputis, Linda A. A. Okoth, Milan Patel, Mariana Seymore, Megan E. V. Caram, Rodney L. L. Dunn, Sofia D. D. Merajver, Elena M. M. Stoffel, Zachery R. R. Reichert, Todd M. M. Morgan
Summary: The study demonstrated the effectiveness of clinician-led genetic counseling in expanding access to appropriate germline genetic testing for prostate cancer patients. Patient satisfaction was high, with majority reporting satisfaction with the quality of counseling and over two-thirds of patients choosing to undergo genetic testing.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Laura K. Sedig, Michelle F. Jacobs, Rajen J. Mody, Lan Q. Le, Natalie J. Bartnik, Michele C. Gornick, Bailey Anderson, Arul M. Chinnaiyan, J. Scott Roberts
Summary: The study reveals both similarities and differences in motivations and attitudes toward paired tumor/germline sequencing between adolescents and parents, with parents having a higher level of understanding and knowledge.
PEDIATRIC BLOOD & CANCER
(2022)
Article
Oncology
Michelle F. Jacobs, Dan Robinson, Yi-Mi Wu, Valerie P. Opipari, Rajen Mody
Summary: This report describes a case of a patient with a history of leukemia and alpha beta hepatosplenic T-cell lymphoma who was diagnosed with ataxia telangiectasia through paired tumor-germline testing. The analysis identified a homozygous pathogenic variant in the ATM gene and uniparental isodisomy as the likely cause of autosomal recessive ataxia telangiectasia. This highlights the importance of considering uniparental isodisomy in the etiology of autosomal recessive conditions.
Editorial Material
Urology & Nephrology
Michelle F. Jacobs, Samantha E. Greenberg
Editorial Material
Urology & Nephrology
Sophia M. Abusamra, Marissa A. Solorzano, Mallory Luke, Jake Quarles, Michelle F. Jacobs, Sanjay Das, Amy Kasputis, Linda A. Okoth, Milan Patel, Mariana Seymore, Megan E. V. Caram, Rodney L. Dunn, Sofia D. Merajver, Elena M. Stoffel, Zachery R. Reichert, Todd M. Morgan
JOURNAL OF UROLOGY
(2022)
Review
Urology & Nephrology
Tyler M. Seibert, Isla P. Garraway, Anna Plym, Brandon A. Mahal, Veda Giri, Michelle F. Jacobs, Heather H. Cheng, Stacy Loeb, Brian T. Helfand, Rosalind A. Eeles, Todd M. Morgan
Summary: Genetic risk assessment can be useful for early detection and prevention of prostate cancer. Rare pathogenic mutations, especially in DNA damage repair genes, increase prostate cancer risk. Common genetic variants can be combined into genetic risk scores, and a high genetic risk score is associated with higher prostate cancer risk. A healthy lifestyle may partially decrease the risk of lethal prostate cancer.
Article
Oncology
Meera Kattapuram, Christina Shabet, Sarah Austin, Michelle F. Jacobs, Erika Koeppe, Emily H. Smith, Lori Lowe, Tobias Else, Kelly B. Cha
Summary: This retrospective study characterizes patients with cutaneous sebaceous lesions (SL), indicating that genetic referral of SL patients with abnormal immunohistochemistry (IHC) can significantly increase the diagnosis rate of Lynch syndrome (LS).
Article
Genetics & Heredity
Michelle F. Jacobs, Erika S. Koeppe, Colby L. Chase, Julia Martinez, Marie-Louise Henry, Jenae M. Osborne, Elena M. Stoffel, Shane C. Quinonez
Summary: Cascade testing, a specific genetic testing method for relatives with inherited conditions, is not widely utilized. We implemented a dedicated clinic model to improve access, decrease wait times, and optimize clinician efficiency for patients seeking cascade testing. The results showed that the clinic significantly shortened wait times, reduced patient drop-off, and improved clinician efficiency.
JOURNAL OF GENETIC COUNSELING
(2023)
Article
Oncology
Lisa M. Maurer, Jessica D. Daley, Elina Mukherjee, Rosemarie E. Venier, Claire M. Julian, Nathanael G. Bailey, Michelle F. Jacobs, Chandan Kumar-Sinha, Haley Raphael, Nivitha Periyapatna, Kurt Weiss, Katherine A. Janeway, Rajen Mody, Peter C. Lucas, Linda M. McAllister-Lucas, Kelly M. Bailey
Summary: The study reveals the impact of BARD1 loss-of-function mutations on Ewing sarcoma treatment response and provides preclinical support for including pediatric patients with pathogenic germline variants in BARD1 in future clinical trials testing novel agents inducing DNA damage or targeting DNA damage repair.
CANCER RESEARCH COMMUNICATIONS
(2022)
Meeting Abstract
Oncology
Nicole Margo Grogan, Yi-Mi Wu, Dan R. Robinson, James M. Rae, Norah Lynn Henry, Daniel F. Hayes, Michelle F. Jacobs, Kara J. Milliron, Bailey Hulswit, Lauren E. Hipp, Sofia Merajver, Elena Martinez Stoffel, Arul Chinnaiyan, Erin Frances Cobain
JOURNAL OF CLINICAL ONCOLOGY
(2021)